Renishaw plc (RSW.L) Bundle
Dive into Renishaw plc's financial landscape where record revenue of £713.0m (up 3.1%) sits alongside an adjusted profit before tax of £127.2m (up 3.8%), a strengthened gross margin of 61.7% and aggressive R&D spend with engineering costs rising to £115.7m; geographically growth is led by a 7.2% constant-currency lift in Asia-Pacific while the Manufacturing Technologies division delivered £671.5m and the Analytical & Medical segment dipped to £41.5m, cash and short-term investments total £273.65m against minimal long-term debt (£15.64m) and a rock‑solid debt-to-equity ratio of 0.02-operating cash flow climbed to £147.9m, free cash flow surged by 686.9% year-over-year, and despite a stable adjusted operating margin of 15.7% and a market consensus price target of £3,530 the stock faces mixed analyst views and clear risks from sector exposure, tariff effects, and ownership uncertainty-keep reading to unpack valuation nuances, solvency signals, and the strategic initiatives shaping Renishaw's next chapter
Renishaw plc (RSW.L) Revenue Analysis
Renishaw plc reported record full-year revenue of £713.0 million for the year ending 30 June 2025, up 3.1% from £691.3 million in FY2024. Growth was concentrated in Manufacturing Technologies, while Analytical Instruments and Medical Devices declined. Geographically, Asia-Pacific led expansion with notable strength in China.
- Total revenue FY2025: £713.0m (+3.1% vs FY2024 £691.3m)
- Manufacturing Technologies: £671.5m (+3.6%) - driven by position encoders and 5-axis CMM systems
- Analytical Instruments & Medical Devices: £41.5m (-3.8%) - neurological product gains offset by lower spectroscopy sales
- H1 FY2025 revenue: £341.4m (+3.0% vs H1 FY2024 £330.5m)
- Geographic trends: Asia‑Pacific +7.2% (constant currency), Americas +2.2%, EMEA flat
- Company expects steady revenue growth in H2 FY2025 supported by strategic initiatives and improved demand
| Metric | FY2025 (£m) | FY2024 (£m) | Change (%) |
|---|---|---|---|
| Total revenue | 713.0 | 691.3 | +3.1 |
| Manufacturing Technologies | 671.5 | 648.4 | +3.6 |
| Analytical Instruments & Medical Devices | 41.5 | 43.1 | -3.8 |
| H1 FY revenue | 341.4 | 330.5 | +3.0 |
| Asia‑Pacific (constant currency) | +7.2% growth (including China) | ||
| Americas | +2.2% | ||
| EMEA | Flat | ||
For deeper investor context and shareholder activity related to these revenue dynamics, see Exploring Renishaw plc Investor Profile: Who's Buying and Why?
Renishaw plc (RSW.L) - Profitability Metrics
Renishaw plc reported mixed profitability signals in FY2025 as operational efficiency improved but one-off costs weighed on statutory results. Adjusted measures show modest growth while statutory figures were impacted by closure-related charges and tax provisions.| Metric | FY2024 | FY2025 | Change |
|---|---|---|---|
| Adjusted profit before tax (£m) | 122.6 | 127.2 | +3.8% |
| Statutory profit before tax (£m) | 122.5 | 118.0 | -3.7% |
| Gross margin (ex. engineering costs) | 61.0% | 61.7% | +0.7 ppt |
| Gross engineering costs (£m) | 106.8 | 115.7 | +8.3% |
| Adjusted operating profit margin | 15.7% | 15.7% | Stable |
| Distribution expenses (change) | - | - | +3.0% |
| Administrative expenses (change) | - | - | +2.7% |
- Adjusted profit before tax rose to £127.2m in FY2025, up 3.8% from £122.6m in FY2024, driven by revenue mix and tighter cost control.
- Statutory profit before tax fell to £118.0m (-3.7%) after recognition of non-recurring facility-closure costs and additional tax provisions.
- Gross margin (excluding engineering) improved to 61.7% versus 61.0% a year earlier, signaling improved operational efficiency and pricing discipline.
- Gross engineering costs increased 8.3% to £115.7m, reflecting sustained R&D and capitalised engineering investment to support long-term product development.
- Distribution and administrative expenses rose modestly (3.0% and 2.7%), consistent with scaling activities and strategic initiatives.
- Adjusted operating profit margin remained stable at 15.7% in FY2025; management has cost-reduction and productivity programs targeting a 20.0% margin over the medium term.
- Investment in engineering: higher upfront costs (FY2025: £115.7m) aimed at sustaining innovation pipeline and future margin expansion.
- Non-recurring items: facility closure charges and tax provisions were the primary drivers of the statutory PBT decline to £118.0m.
- Margin roadmap: maintaining the 15.7% adjusted operating margin while executing efficiency measures to approach a 20% target.
Renishaw plc (RSW.L) Debt vs. Equity Structure
Renishaw's capital structure is heavily weighted toward equity, providing low financial leverage and substantial balance-sheet flexibility. The company reported a debt-to-equity ratio of 0.02 and an equity ratio of 85.9%, underscoring minimal reliance on borrowed funds and a strong equity cushion. Return on equity stood at 10.7%, indicating continued efficiency in using shareholders' funds, albeit lower than earlier periods. Total assets increased to £1.14 billion in FY2025 (from £1.05 billion in FY2024), supported by robust cash generation. Cash, cash equivalents and short-term investments totalled £273.65 million, while total debt remained minimal at £15.64 million.- Debt-to-equity ratio: 0.02 - very low leverage and limited financial risk.
- Equity ratio: 85.9% - strong equity base and capital solidity.
- Return on equity (ROE): 10.7% - efficient use of equity but declining from prior levels.
- Total assets: £1.14 billion (FY2025) vs £1.05 billion (FY2024) - growth driven by cash generation.
- Cash & equivalents: £273.65 million - liquidity for opportunistic investment or buffer.
- Total debt: £15.64 million - minimal long-term indebtedness.
| Metric | FY2024 | FY2025 |
|---|---|---|
| Total assets | £1.05 billion | £1.14 billion |
| Shareholders' equity (approx.) | £902.0 million | £979.3 million |
| Cash, cash equivalents & short-term investments | - | £273.65 million |
| Total debt | - | £15.64 million |
| Debt-to-equity ratio | - | 0.02 |
| Equity ratio | - | 85.9% |
| Return on equity (ROE) | Higher previously | 10.7% |
Key implications for investors:
- Low leverage reduces solvency and refinancing risk, making Renishaw resilient in downturns.
- High equity ratio and substantial cash holdings enhance capacity for R&D, M&A, or dividend distributions.
- ROE of 10.7% shows reasonable profitability on equity, but the decline warrants monitoring of margin trends and capital deployment.
For broader context on the company's background and strategic positioning, see Renishaw plc: History, Ownership, Mission, How It Works & Makes Money
Renishaw plc (RSW.L) - Liquidity and Solvency
Renishaw demonstrates clear improvement in cash generation and a conservative balance-sheet posture. Operating cash flow and free cash flow trends, combined with a strong cash cushion and low leverage, underpin the company's liquidity and solvency profile.- Operating cash flow (FY2025): £147.90m (up from £124.08m in FY2024)
- Free cash flow (FY2025): £58.95m, a 686.9% YoY increase from ~£7.49m in FY2024
- OCF / Net income (FY2025): 1.28 - OCF exceeds reported net income, indicating quality of earnings and cash conversion
- FCF / Net income (FY2025): 0.51 - moderate free-cash generation relative to net earnings
- Cash on balance sheet: nearly £300m, providing flexibility for capex, R&D, dividends or M&A
- Debt & solvency: low reported debt levels and a high equity ratio support strong solvency
| Metric | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | £124.08m | £147.90m |
| Free cash flow | £7.49m (approx.) | £58.95m (approx.) |
| Net income (implied) | n/a | £115.58m (implied from OCF / Net income = 1.28) |
| OCF / Net income | n/a | 1.28 |
| FCF / Net income | n/a | 0.51 |
| Cash on balance sheet | n/a | Nearly £300.0m |
| Debt level | Low | Low |
| Equity / solvency | High equity ratio | High equity ratio |
- Implications for stakeholders: improved OCF supports operational resilience; materially higher FCF provides optionality for shareholder returns or strategic investment.
- Risk considerations: FCF remains ~51% of net income - monitor working-capital swings and capex timing to sustain cash conversion.
Renishaw plc (RSW.L) - Valuation Analysis
Renishaw is currently rated as a 'Hold' with a price target of £3,530, reflecting cautious investor sentiment despite a resilient operating profile. The valuation picture is shaped by mixed analyst views, balance-sheet strength, recurring revenue streams and an ownership-structure overhang that has weighed on the share price.
- Current consensus rating: Hold
- Price target: £3,530
- Analyst breakdown: 3 Buy / 3 Hold / 2 Sell
| Metric | Value / Commentary |
|---|---|
| Consensus rating | Hold |
| Price target | £3,530 |
| Analyst recommendations | 3 Buy, 3 Hold, 2 Sell |
| Primary valuation headwind | Concerns over ownership structure and potential future sales of significant holdings |
| Key valuation tailwinds | Market leadership in precision measurement, recurring revenue streams, strong financial position |
Key drivers behind the Hold rating and cautious price target:
- Ownership and liquidity concerns: Market sensitivity to the potential sale of large insider holdings has elevated perceived execution risk and pressured multiple expansion.
- Mixed analyst sentiment: The 3/3/2 split signals no clear consensus-some analysts see upside from fundamentals, others see limited near-term catalysts.
- Operational resilience: Robust recurring revenues and market-leading positions in metrology and additive manufacturing underpin downside protection for valuation.
- Macro and sentiment effects: Broader market dynamics have depressed investor appetite for cyclical industrial names, amplifying share-price volatility despite stable operations.
Valuation context in numbers (summary of the current market view):
| Item | Figure / Note |
|---|---|
| Official target | £3,530 |
| Analyst split | Buy 3 / Hold 3 / Sell 2 |
| Rating | Hold |
| Principal valuation risk | Potential large-holder sales; investor sentiment |
| Principal valuation support | Strong fundamentals: recurring revenues, market leadership, strategic initiatives |
For more on the company's guiding principles and long-term orientation, see: Mission Statement, Vision, & Core Values (2026) of Renishaw plc.
Renishaw plc (RSW.L) Risk Factors
Renishaw plc (RSW.L) faces a set of interlinked operational, market and structural risks that investors should weigh carefully. Several of these risks have measurable financial impacts today and multiple medium-term implications for revenue, margins and shareholder structure.- Sensors and industrial exposure: demand weakness in the automotive and machine‑tools sectors - particularly in Germany and Taiwan - has weakened the sensors business and reduced near‑term revenue visibility.
- Non‑core neurological divestment: the company is closing the drug‑delivery element of its non‑core neurological business, with completion expected in Q2 FY2026; this reduces recurring revenue but removes a long‑duration operational distraction.
- Tariffs and price pass‑through: U.S. tariffs have created a measurable drag on revenue (reported at roughly a 1% revenue impact), which Renishaw has sought to offset via price increases.
- Currency volatility: FX movements have materially affected reported revenues - management noted a beneficial one‑off FX impact in the prior year that inflated headline growth; conversely recent FX has been a headwind.
- Consumer electronics exposure: even though consumer electronics is cited as an area of relative strength, ongoing volatility in that market adds cyclical risk to demand and inventory dynamics.
- Ownership and governance uncertainty: the death of co‑founder David McMurtry has introduced uncertainty over the long‑term ownership structure, which could weigh on investor sentiment and share performance until clarity on succession and family/estate holdings is established.
| Metric | Latest reported / approximate | Notes |
|---|---|---|
| Reported revenue (most recent full year) | ≈ £400-420m | Currency movements caused notable year‑on‑year variance; prior year included a one‑off FX benefit. |
| Tariff impact | ~1% of revenue (~£4m if revenue ≈£400m) | Companies implemented price increases to mitigate margin erosion. |
| Non‑core drug‑delivery exit | Completion expected Q2 FY2026 | Will remove this revenue line and associated costs/cashflows upon completion. |
| Geographic demand risk | Concentration: Germany & Taiwan (automotive/machine tools) | Weakness in these markets has compressed sensors sales and order intake. |
| Net cash / debt | Management‑reported net cash position historically modestly positive | Balance‑sheet flexibility helps cushion cyclical downturns but depends on cash conversion. |
- Order book sensitivity - a further slowdown in German machine tools or Taiwanese automotive OEM demand could depress sensors revenue by low‑double digits year‑on‑year in stress scenarios.
- Margin pressure - tariff pass‑through has so far been partial; sustained tariffs or further cost inflation (components, freight) could compress operating margins.
- FX exposure - a repeat of the prior year's one‑off favourable FX would materially improve reported results; the reverse is also true.
- Portfolio simplification - exiting the drug‑delivery element should reduce headline complexity but will remove a potential upside if that asset had been retained and scaled.
- Governance / ownership - uncertainty around long‑term holdings after the death of a founder tends to increase share price volatility until estates, trusts or new major holders clarify plans.
Renishaw plc (RSW.L) Growth Opportunities
Renishaw plc has a clear agenda to convert its R&D and product launches into sustained top-line and margin improvement. Recent product introductions and strategic initiatives position the company to capture market share across metrology, encoder technology and semiconductor equipment supply chains.- New products driving future orders: the Equator-X gauging platform and ASTRiA encoder family are positioned for long-term adoption in precision manufacturing and OEM upgrade cycles.
- Geographic expansion: focused growth in Asia‑Pacific (APAC) and the Americas to diversify revenue away from Europe and capture higher-growth regional demand.
- Sector focus: accelerating penetration into semiconductor manufacturing, targeting process-control and lithography metrology applications where precision feedback and encoders command premium pricing.
- Operational efficiency: a company-wide £20 million cost reduction program intended to improve operating margin and free cash flow.
- Innovation pipeline: sustained R&D investment to protect technology leadership and enable premium product pricing and aftermarket recurring revenues (spares, service, calibration).
- Strategic partnerships: pursuing OEM agreements and channel expansion to shorten sales cycles and improve market access in high-growth verticals.
| Metric | Base (most recent FY) | Conservative 3‑yr CAGR | Moderate 3‑yr CAGR | Optimistic 3‑yr CAGR |
|---|---|---|---|---|
| Revenue (GBP, millions) | - (company baseline) | +3% p.a. → illustrative +£X | +6% p.a. → illustrative +£Y | +10% p.a. → illustrative +£Z |
| Operating cost savings (annualised) | £0 | £10m | £20m (programme target) | £25m+ |
| Incremental revenue from Equator-X/ASTRiA (annual) | £0 | £10-20m | £25-40m | £50m+ |
| Semiconductor segment contribution | Low single-digit % of revenue | 5-8% | 8-15% | 15-25% |
| Operating margin uplift (post-savings & product mix) | - | +1-2 p.p. | +3-5 p.p. | +6-8 p.p. |
- Order intake and backlog by product line (Equator-X, ASTRiA, encoders) - monitor quarter-on-quarter growth.
- Revenue split by region (APAC, Americas, EMEA) - track shifts toward APAC/Americas.
- Semiconductor-related revenue and customer wins - number of qualified OEM engagements in Asia.
- Realised cost savings vs. £20m target - monthly/quarterly run‑rate improvement.
- R&D spend as % of revenue and patent filings - signs of continued innovation pipeline strength.
Renishaw plc (RSW.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.